What Are Cell-Penetrating Peptides?

What are cell-penetrating peptides? They are short amino-acid chains that cross a cell’s outer membrane or help attached cargo cross it. Most peptides cannot do that. CPP delivery solves entry, not necessarily useful delivery: many cargos remain trapped in endosomes, and human evidence ranges from an FDA-approved cardiolipin binder to cell-and-mouse-only research.

Why do most peptides struggle to get inside cells?

Most peptides struggle to enter cells because the plasma membrane is an oily barrier around a watery interior. Large, polar, or electrically charged chains do not simply dissolve through that barrier, and enzymes may cut them apart before enough arrives.

Cell-penetrating peptides (CPPs) change that delivery problem. A CPP may be active itself, or carry a protein, nucleic acid, drug, or another peptide through a chemical bond or noncovalent complex. That is the promise behind CPP peptide delivery: use a short entry domain as an access badge for cargo the membrane would normally turn away.

How do TAT and penetratin enter a cell?

TAT and penetratin are early CPPs whose positively charged or mixed charged-and-oily surfaces interact with cell membranes. Depending on the sequence, cargo, dose, and cell type, uptake can occur through endocytosis, where the membrane wraps the material into a vesicle, or by direct translocation across the membrane. No single route explains every CPP.

The TAT peptide study from 1997 narrowed the entry activity of HIV-1 Tat to a short basic domain. Penetratin came from the fruit-fly Antennapedia homeodomain. The original penetratin-style experiment found that 16- and 20-amino-acid fragments entered cultured cells, while a 15-amino-acid fragment did not.

Those early papers described apparently energy-independent entry. Later work found that fixation artifacts and strong peptide binding at the cell surface could exaggerate uptake, especially for arginine-rich CPPs. Endocytosis now explains much TAT entry, though direct translocation can occur under some conditions. The honest answer is less tidy than the brochure version: “inside” depends on how researchers measured it.

Does cellular uptake mean the cargo reaches its target?

Cellular uptake does not guarantee that cargo reaches a useful destination. Endocytosis often leaves a CPP-cargo package sealed inside an endosome, a membrane bubble that may recycle its contents or send them for degradation. Crossing the cell boundary is checkpoint one; escaping the bubble is checkpoint two.

The endosomal escape review describes this as a central limitation. Fluorescence can look like success while active cargo remains quarantined from its target. Useful experiments need to measure a biological effect or cytosolic release, not merely count glowing dots. Cells, regrettably, do not award partial credit for reaching the lobby.

How does SS-31 reach cardiolipin inside mitochondria?

SS-31 is a cell-permeable four-amino-acid peptide that crosses the plasma membrane and concentrates at cardiolipin in the inner mitochondrial membrane. SS-31 is not carrying a separate drug; its own alternating aromatic and positively charged structure provides entry and mitochondrial targeting. Cardiolipin binding places the peptide beside machinery involved in electron transport and ATP production.

The primary SS-31 cardiolipin study used a fluorescent analog, membrane experiments, cultured cells, and rats. The work showed high-affinity cardiolipin binding and protection of mitochondrial cristae during kidney ischemia in rats. That is strong mechanism and animal evidence, not proof of a broad human benefit.

SS-31, also called elamipretide, now has human and regulatory evidence in one narrow lane. FDA granted accelerated approval to Forzinity in 2025 to improve muscle strength in people with Barth syndrome who weigh at least 30 kg. The FDA label says the randomized portion did not beat placebo on its primary walking and fatigue endpoints; approval rested on knee-extensor strength observed during a small open-label extension, with confirmation still required. A larger phase 3 trial in primary mitochondrial myopathy also missed its primary endpoints. Approval for Barth syndrome does not validate SS-31 for fatigue, longevity, or every mitochondrial disorder.

This entry-based family is different from mitochondrial-derived peptides. “Mitochondrial-derived” describes where a peptide’s genetic instructions originate. “Cell-penetrating” describes what a peptide can enter. SS-31 is synthetic, so its destination is mitochondrial even though its origin is not.

Why is FOXO4-DRI called a cell-penetrating peptide?

FOXO4-DRI is cell-penetrating because researchers fused its FOXO4-derived sequence to an HIV-TAT entry domain. The FOXO4-DRI retro-inverso design uses D-amino acids in reverse order to preserve a useful side-chain arrangement while resisting enzymatic breakdown. Entry matters because its proposed target, the FOXO4-p53 protein interaction, sits inside senescent cells.

The 2017 FOXO4-DRI study detected uptake in cultured senescent human fibroblasts within hours. FOXO4-DRI then displaced p53 from FOXO4 and triggered apoptosis, or programmed cell death, preferentially in senescent cells. Experiments in aged and chemotherapy-treated mice reported tissue and functional effects. FOXO4-DRI’s full profile keeps the boundary visible: human cells in a dish are not a human trial, and a ClinicalTrials.gov search found no registered FOXO4-DRI study for people.

What does the evidence actually support?

Cell-penetrating peptides support a proven delivery mechanism in laboratory systems, but “CPP” is not an evidence grade for treatment. Each sequence, cargo, destination, disease, and clinical endpoint needs its own test. SS-31 has reached a narrow accelerated approval; FOXO4-DRI has not crossed from cells and animals into human trials.

Claim	Best evidence	Honest grade
TAT or penetratin domains can enter cultured cells and carry cargo	Cell experiments across many cargo designs	In-vitro delivery evidence
CPP cargo reliably escapes endosomes	Results vary by CPP, cargo, and assay	Unresolved platform limitation
SS-31 binds cardiolipin at the inner mitochondrial membrane	Biophysical, cell, animal, and human pharmacology data	Mechanism supported; outcomes must be graded by disease
Forzinity improves muscle strength in eligible Barth syndrome patients	FDA accelerated approval based on an intermediate endpoint	Human evidence, narrow indication, confirmation pending
FOXO4-DRI clears senescent cells as an anti-aging treatment	Human cells in vitro and mouse studies	Animal-only for whole-body outcomes; none in humans

The practical answer to “what are cell-penetrating peptides?” therefore needs four checks: did the peptide enter, escape an endosome, change its target, and improve a meaningful outcome in a person? That sequence separates a clever delivery system from a treatment claim wearing the same lab coat. The evidence-grading guide shows how to keep those rungs separate.